Drug Trial Radar · NCT05052268
XTX202 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
95
Actual
Start
Jan 18, 2022
Primary completion
Mar 22, 2025
Study completion Mar 25, 2025
Sponsor
- Lead sponsor
- Xilio Development, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202 in Patients with Advanced Solid Tumors
Conditions
- Advanced Solid Tumor
Interventions
XTX202Drug
XTX202 Monotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose Limiting Toxicities (DLTs) (Phase 1 Part 1A Only)Time frame: Cycle 1 day 1 up to just prior to the second dose of study drug at Cycle 2 day 1 (each cycle is 21 days)
- Incidence of Treatment-emergent Adverse Events (Phase 1 Only)Time frame: Up to 24 months
- Investigator-assessed Objective Response Rate (ORR) Per RECIST 1.1 (Phase 2 Only)Time frame: Up to 24 months
- Incidence of Changes in Clinical Laboratory Values (Phase 1 Only) - BiochemistryTime frame: Up to 24 months
- Incidence of Changes in Clinical Laboratory Values (Phase 1 Only) - HematologyTime frame: up to 24 months
- Incidence of Changes in Clinical Laboratory Values (Phase 1 Only) - Thyroid FunctionTime frame: Up to 24 months
- Incidence of Changes in Clinical Laboratory Values (Phase 1 Only) - CoagulationTime frame: Up to 24 months
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
UC San Diego Moores Cancer Center
La Jolla, California
Norris Comprehensive Cancer Center
Los Angeles, California
University of California Los Angeles
Los Angeles, California
Hoag Memorial Hospital Presbyterian- Newport Beach
Newport Beach, California
Georgetown University Medical Center
Washington D.C., District of Columbia
Moffitt Cancer Center
Tampa, Florida
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Massachusetts General Hospital
Boston, Massachusetts
HealthPartners Cancer Center at Regions Hospital
Saint Paul, Minnesota
Atlantic Health System/Morristown Medical Center
Morristown, New Jersey
Rutgers Cancer Institute of NJ
New Brunswick, New Jersey
Carolina BioOncology Institute
Huntersville, North Carolina
The Ohio State University Wexner Medical Center James Cancer Hospital and Solove Research Institute
Columbus, Ohio
UPMC Hillman Cancer Center Pavilion
Pittsburgh, Pennsylvania
Sarah Cannon Research Institute
Nashville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.